Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
FDC Limited is a leading pharmaceutical company in India, engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs). It is particularly noted for its expertise in oral rehydration solutions, energy drinks, antibiotics, and ophthalmic therapies.
The company has expanded its global footprint through two wholly-owned subsidiaries in the USA and UK, and a joint venture in South Africa. FDC is also setting up advanced manufacturing plants to enhance its production capabilities.
FDC has a strategic focus on innovation with ongoing projects like recombinant Granulocyte Colony Stimulating Factor and third-generation thrombolytes. It has received multiple regulatory approvals, including those from the US FDA and European agencies.
The company has executed multiple buybacks and mergers to optimize its equity structure, with significant acquisitions in South Africa, making Fair Deal Corporation Pharmaceutical SA (Pty) Ltd a subsidiary.
In recent years, FDC has diversified its nutraceuticals products, launching multiple energy and immunity-boosting drinks, aligning with modern health and wellness trends. New product launches and expansion into emerging markets continue to drive growth.
Pharmaceuticals & Biotechnology
Pharmaceuticals
6,761 Cr
Low Risk
24.0
37.2
3.0
2.7
528.30
314.75
Sales CAGR
Profit CAGR
ROE
ROCE
Investor Presentation
Q2 FY24
Investor Presentation
Q3 FY23
Investor Presentation
Q2 FY23
Investor Presentation
Q1 FY23
Investor Presentation
Q4 FY22
Investor Presentation
Q4 FY17
Investor Presentation
Q2 FY17
Investor Presentation
Q4 FY16
FDC Ltd (FDC) is currently trading at 415.25 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
FDC Limited is a leading pharmaceutical company in India, engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs). It is particularly noted for its expertise in oral rehydration solutions, energy drinks, antibiotics, and ophthalmic therapies. The company has expanded its global footprint through two wholly-owned subsidiaries in the USA and UK, and a joint venture in South Africa. FDC is also setting up advanced manufacturing plants to enhance its production capabilities. FDC has a strategic focus on innovation with ongoing projects like recombinant Granulocyte Colony Stimulating Factor and third-generation thrombolytes. It has received multiple regulatory approvals, including those from the US FDA and European agencies. The company has executed multiple buybacks and mergers to optimize its equity structure, with significant acquisitions in South Africa, making Fair Deal Corporation Pharmaceutical SA (Pty) Ltd a subsidiary. In recent years, FDC has diversified its nutraceuticals products, launching multiple energy and immunity-boosting drinks, aligning with modern health and wellness trends. New product launches and expansion into emerging markets continue to drive growth.
Over the past 52 weeks, FDC Ltd has traded between a low of ₹314.75 and a high of ₹528.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
FDC Ltd has a market capitalization of approximately 6,794.06. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
FDC Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 24.14 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 6,794.06 Cr, FDC Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
FDC Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of FDC Ltd is 24.14. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
2
Neutral
8
Bullish
4
Bearish
11
Neutral
8
Bullish
27
Bearish
9
Neutral
0
Bullish
23
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
569.15 | 7,075 Cr | 31.89 | 15.15 | 0.79 | 47.50 | 52.11 | 32.88 | ||
215.00 | 6,974 Cr | 4.49 | 5.21 | 0.00 | 116.01 | 80.89 | 71.55 | ||
845.50 | 6,799 Cr | 32.51 | 5.68 | 0.12 | 17.46 | 23.00 | 15.41 | ||
417.80 | 6,794 Cr | 24.14 | 2.73 | 1.20 | 11.32 | 15.18 | 9.64 | ||
1411.50 | 6,500 Cr | 56.34 | 6.96 | 0.00 | 12.36 | 14.43 | 7.58 | ||
685.65 | 6,217 Cr | 33.34 | 2.93 | 0.51 | 8.22 | 9.59 | 5.36 | ||
975.00 | 5,527 Cr | 39.22 | 5.07 | 0.21 | 12.92 | 14.30 | 7.67 | ||
| Median: 7 Co. | — | 685.65 | 6,794 Cr | 32.51 | 5.21 | 0.21 | 12.92 | 15.18 | 9.64 |
Regulatory/Compliance Filing
FDC Ltd submitted a certificate from its RTA (MUFG Intime) under Regulation 74(5) of SEBI (DP) Regulations, 2018 confirming dematerialisation/rematerialisation details for the quarter ended June 30, 2026.
Regulatory/Compliance Filing
FDC Ltd submitted a certificate from RTA MUFG Intime confirming dematerialisation/rematerialisation details for the quarter ended 30-06-2026 as required under Regulation 74(5) of SEBI (DP) Regulations, 2018.
Board Meeting
FDC Ltd informed exchanges its Board will meet on 2026-08-05 to consider and approve unaudited standalone & consolidated financial results for Q1 (ended 30-Jun-2026); trading window remains closed.
Board Meeting
FDC Ltd to hold Board meeting on 2026-08-05 to consider and approve unaudited standalone and consolidated financial results for quarter ended 2026-06-30.
